Quoin Pharmaceuticals, Ltd. — fact timeline

Quoin Pharmaceuticals, Ltd. reported preliminary financial results for first quarter 2026.

“On May 7, 2026 Quoin Pharmaceuticals Ltd. (the “Company”) announced its first quarter 2026 financial results.”

Quoin Pharmaceuticals, Ltd. reported financial results for fourth quarter and fiscal year 2025.

“Quoin Pharmaceuticals Ltd. (the "Company") announced its fourth quarter and fiscal year 2025 financial results. A copy of the Company's press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.”

Quoin Pharmaceuticals, Ltd. issued 15,152 ADSs representing ordinary shares, Pre-Funded Warrants to purchase 1,993,939 ADSs, Series H Warrants to purchase 2,009,091 ADSs, Series I Warrants to pur of unit to institutional and accredited investors for aggregate upfront gross proceeds of approximately $16.6 million (combined purchase price of $8.25 per unit or $8.2499 for pre-funded unit).

“On October 10, 2025, Quoin Pharmaceuticals Ltd. (the "Company" or "Quoin") entered into a Securities Purchase Agreement (the "Purchase Agreement") with several institutional and accredited investors (the "Purchasers") for the issuance and sale in a private placement (the "Private Placement") of securities for gross proceeds at the Closing Date (as defined below) of approximately $16.6 million.”

Quoin Pharmaceuticals, Ltd. engaged CBIZ CPAs P.C. as its auditor.

“CBIZ CPAs was engaged to serve as the independent registered public accounting firm of the Company for the year ending December 31, 2025, effective immediately.”

Marcum LLP resigned as auditor of Quoin Pharmaceuticals, Ltd..

“On March 18, 2025, Marcum resigned as the Company’s independent registered public accounting firm, and CBIZ CPAs was engaged to serve as the independent registered public accounting firm of the Company for the year ending December 31, 2025, effective immediately.”

Quoin Pharmaceuticals, Ltd. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“April 29, 2024, Quoin Pharmaceuticals Ltd. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 31 consecutive business days (March 14, 2024 through April 26, 2024), the Company’s American Depositary Shares (“ADSs”) did not maintain a minimum closing bid price of $1.00 (“Minimum Bid Price Requirement”) per ADS as required by Nasdaq Listing Rule 5550(a)(2). The notice has no immediate effect on the listing or trading of the Company’s ADSs and the ADSs will continue to trade on Th”

Quoin Pharmaceuticals, Ltd. shareholders approved approve the issuance of the maximum number of the Company’s ordinary shares represented by ADSs issuable pursuant to the purchase agreement with Alumni Capital LP at the 2024-04-05 meeting.

“The shareholders approved the Alumni Issuance Proposal. The results of the voting for this proposal were as follows: For Against Abstain Broker Non-Votes 56,626 23,469 2,338 0”

Quoin Pharmaceuticals, Ltd. reported the quarter and year ended December 31, 2023 results: net income Net loss for the quarter ended December 31, 2023 was approximately $2.0 million compared to approximately $2.0 million f.

“Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today provides a business update and announces financial results for the quarter and year ended December 31, 2023.”

Quoin Pharmaceuticals, Ltd. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at cash fee of 7.0% of the aggregate gross proceeds (effective 2024-03-04).

“Pursuant to that certain placement agency agreement, dated March 4, 2024, by and between the Company and the Placement Agent (the "Placement Agency Agreement"), the Placement Agent was paid a cash fee of 7.0% of the aggregate gross proceeds to the Company from the sale of the ADSs, Pre Funded-Funded Warrants and Warrants in the Offering and the Company reimbursed the Placement Agent for (i) non-accountable expenses in an amount of 1.0% of the aggregate gross proceeds raised in the Offering and (ii) accountable expenses of the Placement Agent of $125,000 related to the legal fees.”

Quoin Pharmaceuticals, Ltd. entered into Purchase Agreement with Alumni Capital LP valued at up to $8,000,000 (effective 2024-01-25).

“On January 25, 2024, Quoin Pharmaceuticals Ltd. (the “Company” or “we”) entered into a Purchase Agreement (the “Purchase Agreement”) with Alumni Capital LP (“Alumni”).”

Quoin Pharmaceuticals, Ltd. reported the quarter ended September 30, 2023 results: net income approximately $2.1 million.

“Net loss for the quarter ended September 30, 2023 was approximately $2.1 million compared to approximately $2.3 million for the quarter ended September 30, 2022”

Quoin Pharmaceuticals, Ltd. shareholders approved Approval of the appointment of Marcum LLP as independent registered public accounting firm.

“(14) The shareholders approved the appointment of Marcum LLP as Quoin’s independent registered public accounting firm until Quoin’s 2024 annual meeting of shareholders, as follows: For Against Abstain Brokers non-vote 6,058,620,000 404,820,000 193,020,000 --”

Quoin Pharmaceuticals, Ltd. shareholders voted on Non-binding advisory vote on the frequency of future advisory votes on the compensation of executive officers.

“(11) The shareholders approved, on a non-binding advisory basis, the frequency of future advisory votes on the compensation of Quoin’s executive officers, as follows: 1Y 2 YR 3 YR Abstain Brokers non-vote 1,677,840,000 65,340,000 4,545,480,000 285,840,000 --”

Quoin Pharmaceuticals, Ltd. shareholders approved Non-binding advisory vote on the compensation of named executive officers.

“(10) The shareholders approved, on a non-binding advisory basis, the compensation of Quoin’s named executive officers, as follows: For Against Abstain Brokers non-vote 4,510,560,000 1,855,140,000 290,760,000 --”

Quoin Pharmaceuticals, Ltd. shareholders approved Approval of a grant of options to the Chief Operating Officer.

“(9) The shareholders approved a grant of options to Quoin’s Chief Operating Officer, as follows: For Against Abstain Brokers non-vote 2,222,100,000 1,746,540,000 56,700,000 --”

Quoin Pharmaceuticals, Ltd. shareholders approved Approval of a grant of options to the Chief Executive Officer.

“(8) The shareholders approved a grant of options to Quoin’s Chief Executive Officer, as follows: For Against Abstain Brokers non-vote 2,128,020,000 1,908,960,000 54,540,000 --”

Quoin Pharmaceuticals, Ltd. shareholders approved Approval of an annual discretionary bonus under the terms of employment of the Chief Operating Officer.

“(7) The shareholders approved an annual discretionary bonus under the terms of employment of Quoin’s Chief Operating Officer, as follows: For Against Abstain Brokers non-vote 1,943,280,000 1,631,220,000 544,920,000 --”

Quoin Pharmaceuticals, Ltd. shareholders approved Approval of an annual discretionary bonus under the terms of employment of the Chief Executive Officer.

“(6) The shareholders approved an annual discretionary bonus under the terms of employment of Quoin’s Chief Executive Officer, as follows: For Against Abstain Brokers non-vote 1,929,840,000 1,678,440,000 29,100,000 --”

Quoin Pharmaceuticals, Ltd. shareholders approved Approval of an amendment to the terms of employment of the Chief Operating Officer.

“(5) The shareholders approved an amendment to the terms of employment of Quoin’s Chief Operating Officer, as follows: For Against Abstain Brokers non-vote 4,655,340,000 1,847,220,000 153,900,000 --”

Quoin Pharmaceuticals, Ltd. shareholders approved Approval of an amendment to the terms of employment of the Chief Executive Officer.

“(4) The shareholders approved an amendment to the terms of employment of Quoin’s Chief Executive Officer, as follows: For Against Abstain Brokers non-vote 2,535,360,000 1,501,620,000 55,020,000 --”

Quoin Pharmaceuticals, Ltd. shareholders approved Approval of an amendment to Articles of Association to effect a reverse split at a ratio of 1-for-60,000.

“(3) The shareholders approved an amendment to Quoin’s Articles of Association to effect a reverse split of the Company’s ordinary shares at a ratio of 1-for-60,000, effective on a date to be determined by the Board of Directors of the Company, as follows: For Against Abstain Brokers non-vote 4,318,680,000 2,230,140,000 107,640,000 --”

Quoin Pharmaceuticals, Ltd. shareholders approved Approval of an amendment to Articles of Association to increase registered share capital from 500,000,000,000 to 6,000,000,000,000 ordinary shares.

“(2) The shareholders approved an amendment to Quoin’s Articles of Association, as amended (the “Articles of Association”), to increase the Company’s registered share capital from 500,000,000,000 ordinary shares, no par value, to 6,000,000,000,000 ordinary shares, no par value, as follows: For Against Abstain Brokers non-vote 4,338,900,000 2,218,020,000 99,540,000 --”

Quoin Pharmaceuticals, Ltd. shareholders approved Election of Directors.

“(1) The shareholders elected the following directors to serve on the Board of Directors, to serve until Quoin’s 2024 annual meeting of shareholders and until such director’s successor is duly elected and qualified, or until such director’s earlier resignation or retirement, as follows: Directors For Against Abstain Brokers non-vote Dr. Michael Myers 4,714,440,000 1,171,620,000 770,400,000 -- Denise Carter 5,738,640,000 707,160,000 210,660,000 -- Joseph Cooper 5,743,800,000 692,580,000 220,080,000 -- James Culverwell 5,720,880,000 715,140,000 220,440,000 -- Dr. Dennis H. Langer 5,345,160,000 1,115,640,000 195,660,000 -- Natalie Leong 5,754,360,000 694,500,000 207,600,000 -- Michael Sember 5,734,440,000 584,820,000 337,200,000 --”

Quoin Pharmaceuticals, Ltd. entered into Exclusive License and Distribution Agreement with Farma Mondo SA valued at Exclusive license to commercialize QRX003 in Singapore, royalty-bearing (effective 2023-09-01).

“On September 6, 2023, Quoin Pharmaceuticals Ltd. (the “Company”) entered into an Exclusive License and Distribution Agreement, effective as of September 1, 2023 (the “License Agreement”), with Farma Mondo SA, a company incorporated under the laws of Switzerland (“Farma Mondo”). Pursuant to the License Agreement, the Company granted to Farma Mondo an exclusive license under its Product Technology (as defined in the License Agreement) to commercialize, upon receipt of applicable regulatory approvals, pharmaceutical product QRX003 (in finished dosage form for human use) in Singapore.”

Quoin Pharmaceuticals, Ltd. reported quarter ended June 30, 2023 results: net income Net loss for the quarter ended June 30, 2023 was approximately $2.1 million compared to approximately $2.7 million for t.

“On August 2, 2023, Quoin Pharmaceuticals Ltd. (the “Company”) announced its financial results for the quarter ended June 30, 2023.”

Quoin Pharmaceuticals, Ltd. reported the first quarter of 2023 results: net income approximately $2.6 million.

“Net loss for the quarter ended March 31, 2023 was approximately $2.6 million compared to approximately $1.7 million for the quarter ended March 31, 2022.”

Quoin Pharmaceuticals, Ltd. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“April 5, 2023, Quoin Pharmaceuticals Ltd. (the “Company”) received a letter from the Listing Qualifications staff of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that the closing bid price per American Depositary Share (“ADS”) representing 5,000 ordinary shares of the Company was below the required minimum of $1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirements set forth in Nasdaq Rule 5550(a)(2). Pursuant to Nasdaq Rule 5810(c)(3)(A), the Company has a period of one hundred eighty (180) calendar days, or until”

Quoin Pharmaceuticals, Ltd. reported fourth quarter and full year of 2022 results: net income Net loss for the quarter ended December 31, 2022 was approximately $2.0 million. Net loss for the year ended December 31.

“Net loss for the quarter ended December 31, 2022 was approximately $2.0 million. Net loss for the year ended December 31, 2022 was approximately $9.4 million.”

Quoin Pharmaceuticals, Ltd. entered into Securities Purchase Agreement with certain investors valued at approximately $7 million (effective 2023-02-22).

“On February 22, 2023, Quoin Pharmaceuticals Ltd. (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Investors”), pursuant to which the Company agreed to sell, issue, and deliver, in a registered public offering (the “Offering”) of 24,750,000,000 ordinary shares represented by 4,950,000 American Depositary Shares (“ADSs”) at a purchase price of $1.00 per ADS”